Singapore markets closed
Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
61,138.15 -3,213.90 (-4.99%) CMC Crypto 200
1,262.33 -47.38 (-3.62%)
Alkermes PLC (8AK.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 10:35AM CEST. Market open.
Loading interactive chart…
- PR Newswire
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
- Zacks
Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
© 2024 Yahoo. All rights reserved.